AMH Equity Ltd Sells 113,302 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)

AMH Equity Ltd lowered its position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 59.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 77,198 shares of the medical device company’s stock after selling 113,302 shares during the quarter. AMH Equity Ltd’s holdings in Xtant Medical were worth $34,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC grew its position in shares of Xtant Medical by 70.2% in the 3rd quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company’s stock valued at $348,000 after purchasing an additional 212,394 shares during the period. 69.33% of the stock is owned by hedge funds and other institutional investors.

Xtant Medical Stock Down 3.4 %

XTNT opened at $0.54 on Thursday. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $75.20 million, a P/E ratio of -4.16 and a beta of 0.35. Xtant Medical Holdings, Inc. has a 12 month low of $0.33 and a 12 month high of $1.30.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.